header-bg6.jpg
 
Akili_Logo_simple.png
 

 

A different type of medical product

 

Imagine what medicine can be™

At Akili, we're in the process of building clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like high-quality video games. Our aim is to develop a new type of Digital Medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians. 

Akili was co-founded by PureTech, leading cognitive neuroscientists, and top-tier entertainment software creators. Our operational team is a mix of biomedical scientists and experts in medical device commercialization and interactive design.

science3.png

Scientific Approach

Akili functions on the premise that advances in neuroscience research and consumer-facing technology are enabling a new way to sensitively measure neural function, and intervene in any measured deficits, wherever the patient may be.  Akili's products address both quantitative measurement of and intensive intervention in cognitive functions in a variety of patient populations.

The science behind our first platform, "Project: EVO™", was developed at the University of California, San Francisco by Dr. Adam Gazzaley, Founding Director of the UCSF Neuroscience Imaging Center and Akili's Chief Science Advisor. Dr. Gazzaley's research has led to a patent-pending new software-based method to measure and improve a key system of executive function known as interference processing™. We've deployed these mechanics from the ground up in a consumer videogame interface that runs on mobile phones and tablets, and meets all requirements for rigorous clinical studies. The Project: EVOplatform is currently being tested in a variety of clinical studies in multiple patient populations around the globe, including ADHD, autism, depression, and traumatic brain injury.

cog-background.png

Cognitive Platform

Our cutting-edge cognitive platform (Project: EVO™) enables multiple clinical products for remote data-capture and intervention, with features designed for extreme patient engagement.  Our proprietary adaptive mechanics allow the software to automatically personalize to the patient's ability level with no clinician input required. We're currently validating each product in a variety of specific patient populations.

Treatment Products

IMPROVE NEURAL FUNCTIONING & COGNITIVE SYMPTOMS

Akili's flagship product line from the Project: EVO™ platform provides a targeted way to potentially improve cognition and disease symptoms through entirely at-home digital interactions.  These treatment products provide Akili’s proprietary interference™ processing therapy with the aim of improving symptoms of inattention, working memory, and executive function.  High-res data collection enables patient compliance tracking and progress analytics for multiple stakeholders.   The leading product, Project: EVO™ ADHD, is currently being evaluated in the STARS-ADHD study.  Akili plans to seek approval from the United States Food and Drug administration for this potential first-in-class treatment if the results of the pivotal study are favorable.   Additional customized treatment products from this platform are being tested in Autism, depression, Alzheimer’s disease, and traumatic brain injury.

Monitor Products

FREQUENT AND SENSITIVE COGNITION measurement

We believe that traditional cognitive tests are barely tolerable by the patient and can lack the sensitivity needed for subtle patient characterization and multiple time point engagement. Measurements over time allow for a plethora of uses, from tracking patients' conditions to understanding the effect of interventions on brain function.  Monitor product allows for short measurements configurable to custom tracking needs (hourly, daily, weekly, etc.).  Each individual assessment utilizes the Project: EVO™ platform’s  proprietary measurement of cognitive control in a format that engages the patient. Our goal is higher quality, ultra-frequent, more sensitive cognitive data for use in clinical decision making and clinical trials.

 

 

 
 
 
evo-phone.png

If you want to give your patients a brand new medical experience by running an innovative clinical trial with our software platform, Get in Touch!

partner-background.png

Partnerships

Akili works with top universities and premier partners in the healthcare space to bring our products to market.

Pfizer Pharmaceuticals Pfizer Pharmaceuticals (PFE) is currently funding a study to validate the ability of the Project:EVO™ platform to serve as a biomarker or cognitive endpoint for individuals at risk of developing Alzheimer's disease. We believe that this innovative study is the first in which a pharmaceutical company is using a video game to detect a major disease. The study is currently underway.
Shire Pharmaceuticals In 2013, Shire Pharmaceuticals' (SHPG) Strategic Investment group made a direct investment in Akili. Shire is a market-leader in ADHD medications, and has deep experience in ADHD clinical trials. In addition to the monetary investment, Akili and Shire have worked closely together to structure and launch Akili's first clinical study of the Project:EVO™platform in pediatric ADHD. The three-site study is currently underway.
M Ventures M Ventures joined Akili’s Series B financing in 2016 as an equity investor.  M Ventures (known as Merck Ventures BV outside of the United States and Canada) is the strategic, corporate venture capital arm of Merck KGaA, Germany. Merck KGaA is a leading science and technology company for innovative and top-quality high-tech products in healthcare, life sciences and performance materials.  The portfolio includes prescription medications for cancer, multiple sclerosis, and cardiovascular disorders, among many other products.
Autism Speaks Autism Speaks, through its not-for-profit investment affiliate DELSIA, entered into a clinical collaboration agreement in early 2015 to support a clinical trial of the Project:EVO™platform in children with autism and co-occurring attention deficits. The trial will be a blinded, randomized, placebo-controlled study that will look to measure cognitive and symptom improvement over 1 month of device play. Recruitment will begin in late 2016.

Pfizer Pharmaceuticals (PFE) is currently funding a study to validate the ability of the Project:EVO™ platform to serve as a biomarker or cognitive endpoint for individuals at risk of developing Alzheimer's disease. We believe that this innovative study is the first in which a pharmaceutical company is using a video game to detect a major disease. The study is currently underway.

In 2013, Shire Pharmaceuticals' (SHPG) Strategic Investment group made a direct investment in Akili. Shire is a market-leader in ADHD medications, and has deep experience in ADHD clinical trials. In addition to the monetary investment, Akili and Shire have worked closely together to structure and launch Akili's first clinical study of the Project:EVO™platform in pediatric ADHD. 

M Ventures joined Akili’s Series B financing in 2016 as an equity investor.  M Ventures (known as Merck Ventures BV outside of the United States and Canada) is the strategic, corporate venture capital arm of Merck KGaA, Germany. Merck KGaA is a leading science and technology company for innovative and top-quality high-tech products in healthcare, life sciences and performance materials.  The portfolio includes prescription medications for cancer, multiple sclerosis, and cardiovascular disorders, among many other products.

Amgen Ventures joined Akili’s Series B financing in 2016 as an equity investor.  Amgen Ventures is the strategic ventures capital arm of Amgen and provides emerging innovative companies with financial and other resources to develop pioneering discoveries to treat grievous human illness.  Amgen has a robust product offering and pipeline in oncology, inflammation, and cardiovascular disease.

Autism Speaks, through its not-for-profit investment affiliate DELSIA, entered into a clinical collaboration agreement in early 2015 to support a clinical trial of the Project:EVOplatform in children with autism and co-occurring attention deficits. The trial will be a blinded, randomized, placebo-controlled study that will look to measure cognitive and symptom improvement over 1 month of device play. Recruitment will begin in late 2016.

 

 

Additionally, Akili is in the process of licensing and accelerating product development of the very newest published and as-yet-unpublished neuroscience findings that could address major medical indications.

If you have a research program on a patient population with cognitive deficits, or new science that you would like to develop into engaging medical products, please contact Akili at info@akiliinteractive.com

Akili News

Akili's novel healthcare approach and the technology behind our first product platform has been covered extensively in recent popular and industry-specific media outlets. Stay tuned for more updates!

background.png

Our Team

Our team focuses on merging top science with great user experience. We believe patients deserve better, and we're working to make that a reality

"Why is 'tolerable' the user-experience goal of medicine?  If we make products fun for the patient, we get richer, higher-quality data with a superior experience" - Eddie

"Why is 'tolerable' the user-experience goal of medicine?  If we make products fun for the patient, we get richer, higher-quality data with a superior experience"

- Eddie

Eddie Martucci, PhD

Chief Executive Officer

view bio

"By embracing, rather than fearing, scientific constraints, new and unique game designs can be discovered that would otherwise never have emerged." - Matt O

"By embracing, rather than fearing, scientific constraints, new and unique game designs can be discovered that would otherwise never have emerged."

- Matt O

Matthew Omernick

Chief Creative Officer

view bio

"Running clinical studies is no different with a game than with a traditional device: attention to detail, planning, and the right outcomes make all the difference." - Scott

"Running clinical studies is no different with a game than with a traditional device: attention to detail, planning, and the right outcomes make all the difference."

- Scott

Scott C. Kellogg

VP of Operations

view bio

Kristina Academia

Development Director

view bio

Sandra D. Brown, PhD, Esq

VP of IP & Legal Affairs

view bio

Emre Gulturk

Medical Device QA Manager

view bio

JJ Pic round.png

Jason Johnson

Senior Research & Development Engineer

view bio

Adam Rogers

Senior Engineer

view bio

 
"Data science and neuroscience are both progressing at an unparalleled pace, leaving a vast new landscape of opportunities for non-invasively measuring and driving changes deep within the brain." -Titi

"Data science and neuroscience are both progressing at an unparalleled pace, leaving a vast new landscape of opportunities for non-invasively measuring and driving changes deep within the brain."

-Titi

Titi Ala'ilima

Director of Data Engineering

view bio

David W. Collins

Director of Audio

view bio

Kathryn Jenkins

Clinical Project Manager

view bio

"Medical games will be embraced by the patients because they are engaging and by physicians because they provide unprecedented and unmatched assessments and therapies." -Ashley

"Medical games will be embraced by the patients because they are engaging and by physicians because they provide unprecedented and unmatched assessments and therapies."

-Ashley

Ashley Mateus, PhD

Director of Market Strategy

view bio

  "Video games from the start have been pushing the boundaries of Art, Science and Technology.  Medical game development is one of the most exciting and beneficial intersections of all three." -Jeff 

 

"Video games from the start have been pushing the boundaries of Art, Science and Technology.  Medical game development is one of the most exciting and beneficial intersections of all three."

-Jeff 

Jeff Steinmetz

Principal Architect

view bio

Jimmy Zhou

Data Analyst

view bio

"Video games are data-harnessing machines.  Every frame, every movement tells us something about the user they didn't even know about themselves" - Bower

"Video games are data-harnessing machines.  Every frame, every movement tells us something about the user they didn't even know about themselves"

- Bower

Jeffery Bower, PhD

Director of Data Science

view bio

Dan Goddard

Operations Manager

view bio

"In all our efforts (whether scientific, technical, or creative) we always need to try and remember - what is the problem we are trying to solve?" - Frank

"In all our efforts (whether scientific, technical, or creative) we always need to try and remember - what is the problem we are trying to solve?"

- Frank

Frank Hickman

Principal Engineer

view bio

"It’s rewarding to blaze a trail that can make a difference.  The design, code, and all of us have traveled creative roads that we wouldn’t have otherwise traveled" - Piper

"It’s rewarding to blaze a trail that can make a difference.  The design, code, and all of us have traveled creative roads that we wouldn’t have otherwise traveled"

- Piper

Adam Piper

Lead Engineer / Designer

view bio

Kristin Vaselacopoulos

Office, Style & Events Manager

view bio

 
 

Our Board

 

 
Adam Gazzaley, MD PhD Board Member view bio

Adam Gazzaley, MD PhD

Board Member

view bio

Ben Shapiro, MD Board Member view bio

Ben Shapiro, MD

Board Member

view bio

Eric Elenko, PhD Board Member view bio

Eric Elenko, PhD

Board Member

view bio

Daphne Zohar Board Member view bio

Daphne Zohar

Board Member

view bio

 
 
Joi Ito Board Member view bio

Joi Ito

Board Member

view bio

Jamie Gates Board Member view bio

Jamie Gates

Board Member

view bio

John Spinale Board Member view bio

John Spinale

Board Member

view bio

 
 
 

Our Advisors

 
Geraldine Dawson, PhD view bio

Geraldine Dawson, PhD

view bio

Steve Faraone, PhD view bio

Steve Faraone, PhD

view bio

Maurizio Fava, PhD view bio

Maurizio Fava, PhD

view bio

Robert T. Schultz, PhD view bio

Robert T. Schultz, PhD

view bio

 
 
Daphne Bavelier, PhD Co-Founding Advisor view bio

Daphne Bavelier, PhD

Co-Founding Advisor

view bio

Philip Rosedale Co-Founding Advisor view bio

Philip Rosedale

Co-Founding Advisor

view bio

 
white-graph2.png

 

Get In Touch!

Someone from the Akili team will get back to you shortly.

 
 
 

Welcome to the interactive medicine revolution™